TBPH
Theravance Biopharma Inc

1,011
Mkt Cap
$898.42M
Volume
526,831.00
52W High
$18.96
52W Low
$7.90
PE Ratio
31.52
TBPH Fundamentals
Price
$17.90
Prev Close
$17.73
Open
$17.88
50D MA
$14.81
Beta
0.57
Avg. Volume
288,777.87
EPS (Annual)
-$1.16
P/B
3.86
Rev/Employee
$663,721.65
Loading...
Loading...
News
all
press releases
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 Theravance Biopharma to...
PR Newswire·7h ago
News Placeholder
More News
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Makes New $624,000 Investment in Theravance Biopharma, Inc. $TBPH
Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the second quarter, according to its most recent Form...
MarketBeat·14h ago
News Placeholder
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·1d ago
News Placeholder
Theravance Biopharma to Participate in Upcoming Investor Conferences
Theravance Biopharma to Participate in Upcoming Investor Conferences Theravance Biopharma to Participate in Upcoming Investor Conferences PR Newswire DUBLIN, Nov. 19, 2025 DUBLIN, Nov. 19, 2025...
PR Newswire·2d ago
News Placeholder
Los Angeles Capital Management LLC Buys Shares of 19,850 Theravance Biopharma, Inc. $TBPH
Los Angeles Capital Management LLC bought a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC...
MarketBeat·2d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down - Should You Sell?
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down - Here's What Happened...
MarketBeat·7d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High on Analyst Upgrade
Theravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month High After Analyst Upgrade...
MarketBeat·8d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Posts Earnings Results, Hits Estimates
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, meeting the consensus...
MarketBeat·9d ago
News Placeholder
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Zacks·9d ago
News Placeholder
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago

Latest TBPH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.